These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 3287388

  • 21. Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.
    Labrie F, Dupont A, Cusan L, Gomez J, Emond J, Monfette G.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):943-50. PubMed ID: 2285608
    [Abstract] [Full Text] [Related]

  • 22. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Belanger A, Lachance R, Emond J, Monfette G.
    J Steroid Biochem; 1987 Dec 20; 27(1-3):525-32. PubMed ID: 2961937
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effect of 3-week treatment with [D-Trp6, des-Gly-NH10(2)]LHRH ethylamide, aminoglutethimide, ketoconazole or flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog.
    Lacoste D, Caron S, Bélanger A, Labrie F.
    J Steroid Biochem; 1989 Aug 20; 33(2):233-42. PubMed ID: 2671505
    [Abstract] [Full Text] [Related]

  • 25. Combination hormonal therapy: a reassessment within advanced prostate cancer.
    Moul JW, Chodak G.
    Prostate Cancer Prostatic Dis; 2004 Sep 20; 7 Suppl 1():S2-7. PubMed ID: 15365575
    [Abstract] [Full Text] [Related]

  • 26. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
    Matveev BP, Bukharkin BV.
    Vopr Onkol; 1998 Sep 20; 44(5):537-40. PubMed ID: 9884710
    [Abstract] [Full Text] [Related]

  • 27. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects.
    Fleshner NE, Trachtenberg J.
    J Urol; 1995 Nov 20; 154(5):1642-5; discussion 1645-6. PubMed ID: 7563310
    [Abstract] [Full Text] [Related]

  • 28. Health-related quality of life among patients with metastatic prostate cancer.
    Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE.
    Urology; 1997 Feb 20; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A.
    J Urol; 2000 Mar 20; 163(3):838-44. PubMed ID: 10687989
    [Abstract] [Full Text] [Related]

  • 33. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
    Teillac P, Bono AV, Irani J, Wirth MP, Zlotta AR.
    Clin Ther; 2005 Mar 20; 27(3):273-85. PubMed ID: 15878381
    [Abstract] [Full Text] [Related]

  • 34. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, Raynaud JP, Husson JM.
    Clin Invest Med; 1982 Mar 20; 5(4):267-75. PubMed ID: 6819101
    [Abstract] [Full Text] [Related]

  • 35. Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up.
    Lee F, Bahn DK, McHugh TA, Kumar AA, Badalament RA.
    Anticancer Res; 1997 Mar 20; 17(3A):1511-5. PubMed ID: 9179188
    [Abstract] [Full Text] [Related]

  • 36. Induction and maintenance of castration by an LHRH analogue: D-Trp6 LHRH or decapeptyl.
    Fretin J, Demerle F, Jardin A.
    Prog Clin Biol Res; 1987 Mar 20; 243A():245-7. PubMed ID: 2958855
    [No Abstract] [Full Text] [Related]

  • 37. Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide.
    Cusan L, Gomez JL, Dupont A, Diamond P, Lemay M, Moore S, Labrie F.
    Prostate; 1994 May 20; 24(5):257-61. PubMed ID: 7513417
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Hormone chemotherapy for newly diagnosed patients with metastatic prostate cancer.
    Kubota Y, Nakada T, Suzuki Y, Iizima Y, Adachi Y, Hashimoto T.
    Int Urol Nephrol; 1993 May 20; 25(5):469-74. PubMed ID: 8270375
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.